These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 21913988

  • 1. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG, Reilly RF.
    Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
    [Abstract] [Full Text] [Related]

  • 2. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [Abstract] [Full Text] [Related]

  • 3. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J.
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK.
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [Abstract] [Full Text] [Related]

  • 5. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H.
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [Abstract] [Full Text] [Related]

  • 6. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P, Skov L.
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 8. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S, Walter S, Witzke O, Kreuter A, Kribben A, Mitchell A.
    Nephron Clin Pract; 2012 Oct; 121(1-2):c91-4. PubMed ID: 23182840
    [Abstract] [Full Text] [Related]

  • 9. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC, Abu-Alfa AK.
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [Abstract] [Full Text] [Related]

  • 10. Nephrogenic systemic fibrosis.
    Weinreb JC, Kuo PH.
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [Abstract] [Full Text] [Related]

  • 11. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 12. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep 01; 47(5):871-5, vii. PubMed ID: 19744601
    [Abstract] [Full Text] [Related]

  • 13. Prevention of iodinated contrast induced acute kidney injury (ICI--AKI) - what have we learnt so far?
    Asim M.
    Saudi J Kidney Dis Transpl; 2009 Sep 01; 20(5):753-65. PubMed ID: 19736469
    [Abstract] [Full Text] [Related]

  • 14. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS.
    JAMA Intern Med; 2020 Feb 01; 180(2):223-230. PubMed ID: 31816007
    [Abstract] [Full Text] [Related]

  • 15. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM, Port M, Dencausse A, Lancelot E, Corot C.
    Radiol Clin North Am; 2009 Sep 01; 47(5):855-69, vii. PubMed ID: 19744600
    [Abstract] [Full Text] [Related]

  • 16. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E, Semelka RC, Cakit C.
    Acad Radiol; 2009 Jul 01; 16(7):897-905. PubMed ID: 19375360
    [Abstract] [Full Text] [Related]

  • 17. Toxicity of contrast media: an update.
    ten Dam MA, Wetzels JF.
    Neth J Med; 2008 Nov 01; 66(10):416-22. PubMed ID: 19011267
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M, Burkhalter F, Bongartz G.
    J Magn Reson Imaging; 2009 Dec 01; 30(6):1289-97. PubMed ID: 19937929
    [Abstract] [Full Text] [Related]

  • 19. The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis.
    Hashemi P, Sina B, Rietkerk W, Safai B.
    J Nephrol; 2013 Dec 01; 26(1):48-54. PubMed ID: 22573525
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.